Key regions: India, Japan, France, Brazil, South Korea
Anti-Fibrinolytic Drugs are used to prevent the breakdown of blood clots in the body. In Iran, the market for these drugs has been developing steadily over the past few years.
Customer preferences: There is a growing demand for Anti-Fibrinolytic Drugs in Iran due to an increase in the number of surgeries being performed. Patients who undergo surgery are at risk of excessive bleeding, and these drugs help to prevent this from happening. Additionally, there is a growing awareness among the population about the benefits of these drugs, which has led to an increase in demand.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Iran is the shift towards more advanced and effective drugs. There is a growing preference for drugs that are more targeted and have fewer side effects. This trend is being driven by advancements in medical research and technology, as well as increasing competition in the market.Another trend in the market is the increasing use of generic drugs. This is due to the lower cost of these drugs, which makes them more accessible to a wider range of patients. Additionally, there is a growing trend towards self-medication, which has led to an increase in demand for over-the-counter Anti-Fibrinolytic Drugs.
Local special circumstances: One of the unique aspects of the Anti-Fibrinolytic Drugs market in Iran is the role of the government. The Iranian government heavily regulates the pharmaceutical industry, which has led to a more stable market. Additionally, the government has implemented policies to encourage the production of generic drugs, which has helped to increase access to these drugs.
Underlying macroeconomic factors: The Iranian economy has been facing significant challenges in recent years, including sanctions and inflation. However, the pharmaceutical industry has remained relatively stable due to government support and a growing demand for healthcare services. As the population continues to age and healthcare needs increase, the demand for Anti-Fibrinolytic Drugs is expected to continue to grow.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
